Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Metformin on hepatic venous pressure gradient in patients with cirrhosis and portal hypertension
2023-508535-32-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Portal Hypertension (PH) and Cirrhosis comparing Metformin with Placebo (2 arms). Primary endpoints: HVPG after 28 days of treatment and Postprandial systemic haemodynamics and HVPG changes. Planned start Mar 2025; status: authorised.
02
Drugs
metformin
03
Conditions
Portal Hypertension (PH)Cirrhosis
Beyond the preview
Go deeper on 2023-508535-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508535-32-00.